News Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Mar 18, 2019

InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology
Mar 13, 2019

InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program
Mar 12, 2019

InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on March 19, 2019
Mar 6, 2019

InMed Pharmaceuticals Appoints Dr. Steven M. Dinh to Scientific Advisory Board
Feb 12, 2019

InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
Feb 5, 2019

InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019
Jan 11, 2019

InMed Pharmaceuticals Announces the Appointment of Dr. Sazzad Hossain, PhD, MSc, as a Member of the Scientific Advisory Board and his Retirement as Chief Scientific Officer
Jan 3, 2019

InMed Pharmaceuticals to Present at Biotech Showcase 2019 on January 9, 2019
Dec 4, 2018

InMed Pharmaceuticals Receives Funding from the Government of Canada to Support Development of Novel Cannabinoid Biosynthesis Program
Nov 12, 2018

InMed Pharmaceuticals Reports First Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
Nov 5, 2018

InMed Pharmaceuticals to Report First Quarter Fiscal 2019 Financial Results and Business Update on November 12, 2018
Nov 5, 2018

InMed Pharmaceuticals Appoints Michael Woudenberg as Vice President, Chemistry, Manufacturing, and Controls
Oct 10, 2018

InMed Pharmaceuticals to Present at BIO Investor Forum on October 17, 2018
Oct 3, 2018

InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada for Cannabinoid Biofermentation Process Development and Scale-Up
Sep 25, 2018

InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
Sep 13, 2018

InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update
Sep 11, 2018

InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
Sep 10, 2018

InMed Files Patent Application for its Cannabinoid Biosynthesis Program
Sep 7, 2018

InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018
Aug 31, 2018

InMed Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
Aug 1, 2018

InMed to Present at the Canaccord Genuity 38th Annual Growth Conference
Jun 21, 2018

InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter's Over-Allotment Option
May 29, 2018

InMed to Present at the 8th Annual LD Micro Invitational Conference
May 14, 2018

InMed Files Patent Application for INM-085 Glaucoma Program
May 11, 2018

InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update
May 1, 2018

InMed Appoints Dr. Vikramaditya G. Yadav to Scientific Advisory Board
Apr 17, 2018

InMed Rings the Opening Bell at the Toronto Stock Exchange
Apr 11, 2018

InMed Announces Appointment of Joshua Blacher as Chief Business Officer
Mar 23, 2018

InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange
Mar 13, 2018

InMed Appoints Dr. Eric Hsu as Vice President, Preclinical Research and Development
Mar 12, 2018

InMed to Present at 30th Annual ROTH Capital Conference
Mar 6, 2018

InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research
Mar 2, 2018

InMed Receives Conditional Approval to List on the Toronto Stock Exchange
Jan 23, 2018

InMed To Present At Canaccord Genuity Conference
Jan 4, 2018

InMed Closes Over-Subscribed C$9.4 Million Financing
Dec 20, 2017

InMed Clarifies 3rd Party News Coverage
Dec 18, 2017

InMed Announces Non-Brokered Private Placement
Nov 16, 2017

InMed to Present at Cannabis-Based Science & Medicine Conference
Oct 24, 2017

InMed Announces Positive Pre-Clinical Data on an Ocular Hydrogel Formulation using a Biosynthesized Cannabinoid
Oct 17, 2017

InMed Updates Pain Program
Oct 10, 2017

InMed Appoints Dr. Mauro Maccarrone to its Scientific Advisory Board
Oct 3, 2017

InMed Pharmaceuticals Files Provisional Patent for Pain Program
Sep 25, 2017

InMed Continues to Make Significant Strides on Biosynthesis Program Development
Sep 21, 2017

InMed Pharmaceuticals Added to CSE25 Index
Sep 19, 2017

InMed Retains Consultant Ben Paterson for Biosynthesis Development
Sep 12, 2017

InMed Files Provisional Patent for Biosynthesis of Cannabinoids
Aug 18, 2017

InMed Announces Appointment of Creative Capital Media
Jul 27, 2017

InMed Announces Publication in European Journal of Pain
Jul 10, 2017

InMed Signs R&D Agreement with ATERA
Jun 13, 2017

InMed Announces Agreement to Advance a Topical Formulation of INM-750
May 31, 2017

InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option
May 23, 2017

InMed Announces Pricing of $5,004,000 Underwritten Financing
May 10, 2017

InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery
Apr 21, 2017

InMed Pharmaceuticals Announces Marketed Offering of Common Shares
Mar 24, 2017

InMed Pharmaceuticals Shareholders Approve New Stock Option Plan and Articles
Mar 8, 2017

InMed Pharmaceuticals to Present at the 29th Annual ROTH Conference
Mar 2, 2017

InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex
Feb 27, 2017

InMed Receives over $1,350,000 From Warrant Exercise
Feb 9, 2017

InMed Pharmaceuticals to Present at the 2017 BIO CEO & Investor Conference
Jan 18, 2017

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,500,000
Jan 13, 2017

InMed Pharmaceuticals Appoints Martin Bott to Board of Directors
Jan 9, 2017

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$1,000,000
Jan 9, 2017

InMed Launches New Website
Dec 23, 2016

InMed Provides 2016 Year End Update
Dec 15, 2016

InMed Pharmaceuticals Announces Appointment of Veteran Biotech CFO, Jeff Charpentier
Dec 6, 2016

InMed announces progress on COPD program
Nov 23, 2016

InMed to Present at Cannabis-Based Therapies Conference
Oct 31, 2016

InMed Pharmaceuticals, Inc. Appoints Senior Vice President, Clinical and Regulatory Affairs
Oct 27, 2016

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,500,000
Oct 4, 2016

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$1,500,000
Sep 13, 2016

InMed Appoints Andrew Hull to the Board of Directors
Sep 12, 2016

InMed to Present at 18th Annual Rodman and Renshaw Global Investment Conference
Jul 28, 2016

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$304,500
Jul 19, 2016

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$250,000
Jun 16, 2016

InMed Announces Appointment of Eric A. Adams as CEO, President and Director
Jun 13, 2016

InMed Announces Appointment of William J. Garner, M.D. to its Board of Directors
May 18, 2016

InMed Updates Progress of its Epidermolysis Bullosa Program
May 4, 2016

InMed Pharmaceuticals Provides Strategic Update on its Business Plans, Announces Planned Executive and Board Departures
Feb 16, 2016

InMed Announces Update on Biosynthesis Project
Nov 23, 2015

InMed Strengthens Board with Appointment of Experienced Biotech Executive Adam Cutler
Nov 4, 2015

InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa
Nov 2, 2015

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000
Sep 3, 2015

InMed Appoints Paul Brennan as President & Chief Executive Officer
Sep 2, 2015

InMed Commences Development of Proprietary Drug Delivery System
Aug 25, 2015

InMed Appoints Paul Brennan to the Board of Directors
Aug 20, 2015

InMed Pharmaceuticals Announces Progress in Orofacial Pain Program
Aug 6, 2015

InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)
Jun 3, 2015

InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline
May 26, 2015

InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS)
May 12, 2015

InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases
May 7, 2015

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,232,750
May 5, 2015

InMed Engages Peter Mountford as Strategic Advisor
Apr 30, 2015

InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S.
Apr 15, 2015

InMed Awarded Grant for Proprietary Nanoparticle-Based Delivery System for Glaucoma Therapy
Apr 6, 2015

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000
Mar 31, 2015

InMed Pharmaceuticals Strengthens Scientific Advisory Board
Mar 23, 2015

InMed Receives Exemption Status from Health Canada
Mar 20, 2015

InMed Pharmaceuticals added to CSE Composite Index
Mar 18, 2015

InMed Initiates Pre-clinical Work on Orofacial Pain
Mar 10, 2015

InMed Forms Strategic Collaboration to Develop Novel Phytocannabinoid Therapies for Ocular Allergies

Show per page

Investor

News Releases

Investor Alerts

Information Request

Stay up to Date

Investor

Investor Alerts

Information Request

Stay up to Date​

Stay up to Date